Creative Planning Boosts Stake in IDEAYA Biosciences, Inc. $IDYA

Creative Planning boosted its stake in IDEAYA Biosciences, Inc. (NASDAQ:IDYA) by 99.4% in the 2nd quarter, according to its most recent filing with the SEC. The fund owned 121,684 shares of the company’s stock after purchasing an additional 60,667 shares during the period. Creative Planning owned about 0.14% of IDEAYA Biosciences worth $2,558,000 at the end of the most recent quarter.

Other large investors also recently added to or reduced their stakes in the company. Mitsubishi UFJ Asset Management Co. Ltd. grew its stake in shares of IDEAYA Biosciences by 9.1% in the first quarter. Mitsubishi UFJ Asset Management Co. Ltd. now owns 7,483 shares of the company’s stock valued at $123,000 after buying an additional 627 shares in the last quarter. CWM LLC increased its position in shares of IDEAYA Biosciences by 33.0% during the second quarter. CWM LLC now owns 3,153 shares of the company’s stock worth $66,000 after acquiring an additional 782 shares during the period. PNC Financial Services Group Inc. raised its stake in shares of IDEAYA Biosciences by 39.1% in the second quarter. PNC Financial Services Group Inc. now owns 3,344 shares of the company’s stock valued at $70,000 after acquiring an additional 940 shares in the last quarter. Police & Firemen s Retirement System of New Jersey boosted its holdings in IDEAYA Biosciences by 6.7% in the second quarter. Police & Firemen s Retirement System of New Jersey now owns 18,878 shares of the company’s stock valued at $397,000 after purchasing an additional 1,191 shares during the period. Finally, Swiss National Bank grew its stake in IDEAYA Biosciences by 0.8% during the 1st quarter. Swiss National Bank now owns 150,800 shares of the company’s stock worth $2,470,000 after purchasing an additional 1,200 shares in the last quarter. 98.29% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

Several research firms recently commented on IDYA. Guggenheim assumed coverage on IDEAYA Biosciences in a report on Thursday, September 18th. They issued a “buy” rating and a $50.00 target price on the stock. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of IDEAYA Biosciences in a report on Wednesday, October 8th. The Goldman Sachs Group lifted their price objective on shares of IDEAYA Biosciences from $27.00 to $30.00 and gave the company a “neutral” rating in a research note on Tuesday, October 21st. BTIG Research reaffirmed a “buy” rating and issued a $62.00 target price on shares of IDEAYA Biosciences in a report on Tuesday, October 21st. Finally, Truist Financial set a $59.00 price target on IDEAYA Biosciences in a report on Monday. Fifteen analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $46.40.

IDEAYA Biosciences Stock Performance

IDYA opened at $34.67 on Tuesday. The company has a market cap of $3.04 billion, a price-to-earnings ratio of -18.64 and a beta of 0.14. IDEAYA Biosciences, Inc. has a one year low of $13.45 and a one year high of $35.12. The business’s fifty day moving average is $29.22 and its two-hundred day moving average is $24.82.

IDEAYA Biosciences (NASDAQ:IDYA) last released its quarterly earnings results on Tuesday, November 4th. The company reported $1.33 earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.12) by $1.45. The firm had revenue of $207.83 million for the quarter, compared to analyst estimates of $59.98 million. On average, analysts predict that IDEAYA Biosciences, Inc. will post -3.07 EPS for the current fiscal year.

IDEAYA Biosciences Profile

IDEAYA Biosciences, Inc, a synthetic lethality-focused precision medicine oncology company, discovers and develops targeted therapeutics for patient populations selected using molecular diagnostics in the United States. The company's products in development include IDE196, a protein kinase C inhibitor that is in Phase 2/3 clinical trials for genetically defined cancers having GNAQ or GNA11 gene mutations; IDE397, a methionine adenosyltransferase 2a inhibitor that is in Phase 1/2 clinical trials for patients with solid tumors having methylthioadenosine phosphorylase gene deletions, such as non-small cell lung, bladder, gastric, and esophageal cancers; IDE161, a poly ADP-ribose glycohydrolase inhibitor that is in Phase 1 clinical trial to treat tumors with homologous recombination deficiency (HRD), and other genetic or molecular signatures; GSK101, a Pol Theta Helicase inhibitor that is in Phase 1 clinical trial for the treatment of tumors with BRCA or other homologous recombination, and HRD mutations; and Werner Helicase inhibitors for tumors with high microsatellite instability.